Ar­cus grabs US rights to a WuXi-built PD-1 as sec­ond wave of check­points builds

West Coast up­start Ar­cus Bio­sciences has bagged its very own PD-1 an­ti­body to take in­to the clin­ic with its im­muno-on­col­o­gy pipeline drugs.

Ar­cus turned to WuXi Bi­o­log­ics and its Chi­nese part­ner Harbin Glo­ria Phar­ma­ceu­ti­cals for re­gion­al North Amer­i­can, Eu­ro­pean and Japan­ese rights to GLS-010. The US biotech is pay­ing $18.5 mil­lion up­front along with a po­ten­tial moth­er­load of de­vel­op­ment and sales mile­stones amount­ing to $816 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.